Overview

Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Status:
Completed
Trial end date:
2008-11-11
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose cyclophosphamide in patients with severe aplastic anemia. II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide shortens the time to recovery in these patients. III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal hemoglobinuria.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Treatments:
Cyclophosphamide